TCA
PRME icon

Transcend Capital Advisors’s Prime Medicine PRME Stock Holding History

Transcend Capital Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,070
Closed -$105K – 845
2026
Q1 		$105K Buy
30,070
+3,570
+13% +$13.6K 0.01% 707
2025
Q4 		$92K Buy
+26,500
New +$118K 0.01% 676

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Transcend Capital Advisors's PRME Position: Q2 2026 in Review

Transcend Capital Advisors sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 30,070 shares — an estimated $105K sold.

Transcend Capital Advisors first reported a position in PRME in Q4 2025 and held it in 2 quarters. The position peaked at $105K in Q1 2026. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Transcend Capital Advisors reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Transcend Capital Advisors sold 30,070 Prime Medicine shares in Q2 2026, an estimated $105K.
  • Transcend Capital Advisors first reported a position in Prime Medicine in Q4 2025 and held it in 2 quarters.
  • Transcend Capital Advisors's Prime Medicine position peaked at $105K in Q1 2026.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.